Mural Oncology (NASDAQ:MURA) Receives New Coverage from Analysts at Rodman & Renshaw

Rodman & Renshaw began coverage on shares of Mural Oncology (NASDAQ:MURA) in a research report released on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $15.00 price objective on the stock.

Separately, Morgan Stanley began coverage on Mural Oncology in a research report on Thursday, April 4th. They set an overweight rating and a $13.00 price objective for the company.

Mural Oncology Price Performance

Shares of Mural Oncology stock opened at $3.14 on Friday. Mural Oncology has a one year low of $3.03 and a one year high of $17.00. The business has a 50-day simple moving average of $3.52 and a 200-day simple moving average of $4.28.

Mural Oncology (NASDAQ:MURA) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($1.84) EPS for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.82. As a group, equities research analysts forecast that Mural Oncology will post -7.54 earnings per share for the current year.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.